Use of finerenone was associated with a statistically significant 25% relative reduction in urine albumin-to-creatinine ratio compared with placebo over 6 months in patients with
FINE-ONE: Finerenone Proves Benefit in Type 1 Diabetes and CKD
Use of finerenone was associated with a statistically significant 25% relative reduction in urine albumin-to-creatinine ratio compared with placebo over 6 months in patients with